Skip to content

Bio-Rad Laboratories BIO Restricted Cash

Restricted Cash at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$202M+153%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
Charles River Laboratories logo
Charles River LaboratoriesCRL
Bruker logo
BrukerBRKR

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's restricted cash?
Bio-Rad Laboratories (BIO) reported restricted cash of $1.6M in Q1 2026.
How has Bio-Rad Laboratories's restricted cash changed year-over-year?
Bio-Rad Laboratories's restricted cash increased by 23.1% year-over-year, from $1.3M to $1.6M.
What is the long-term trend for Bio-Rad Laboratories's restricted cash?
Over 2 years (2022 to 2024), Bio-Rad Laboratories's restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $5.56M to $0.